Primary thyroid gland myxofibrosarcoma: a case report and review of the literature

Maria Chara Stylianidi¹, Lena Haeberle², Matthias Schott³, Yuriko Mori⁴, Christina Antke⁴, Frederick Lars Giesel⁴, Gerald Antoch⁵, Irene Esposito², Wolfram Trudo Knoefel¹ and Andreas Krieg¹*

Abstract

Background: Myxofibrosarcoma is a common soft tissue sarcoma of the extremities, which occurs very rarely in the thyroid gland.

Case presentation: We report the case of a 61-year-old male who presented with a swelling of the left side of the neck and a newly emerged hoarseness. Ultrasound depicted a hypoechoic thyroid nodule with microcalcifications that was highly suspicious for malignancy. He underwent a left hemithyroidectomy. Histopathological examination and immunohistochemical studies revealed a myxofibrosarcoma of the thyroid gland.

Conclusion: Myxofibrosarcoma of the thyroid gland is extremely rare. The diagnosis is based on histopathological features. Radical surgery achieving tumor-free resection margins remains the only chance for cure. However, the role of radiotherapy and/or chemotherapy is still under debate. Due to their high tendency for locoregional recurrence, a close follow-up after surgery is mandatory.

Keywords: Soft tissue sarcoma, Myxofibrosarcoma, Thyroid gland

Background

Myxofibrosarcoma (MFS) is one of the most common malignant soft-tissue neoplasms in elderly patients and has a slight male predominance [1]. MFS appear as mucoid and nodular lesions with a coarse plexiform capillary growth pattern composed of pleomorphic spindle-shaped cells in a myxoid and hypocellular background. However, in high-grade tumors more solid and cellular areas can be observed [2, 3]. Most frequently, these tumors appear within the dermis and subcutis or in the skeletal muscle of the extremities, but there are a few cases reported in which MFS is appearing in the head and neck region, including the hypopharynx [4]. Independent of the localization, complete resection of MFS with tumor-free resection margins remains the gold standard for optimal local tumor control. Whereas this therapeutic regimen might be suitable for small, low-grade or superficial tumors, for large high-grade intramuscular MFS, adjuvant chemo- or radiotherapy may be indicated. However, the 5-year local recurrence rate for MFS of the extremity is with 14.6% comparable to that of other soft tissue sarcoma (STS) subtypes [5]. To our knowledge, there are only 4 cases reported that involve the thyroid gland and that were diagnosed postoperatively (Table 1) [6–9].

Case presentation

A 61-year-old male presented at our emergency department with a swelling of the left side of the neck that increased over a period of 4–6 weeks and hoarseness. Clinical examination revealed a clearly visible enlarged, hard, and fixed left thyroid gland. Fiberoptic laryngoscopy was able to exclude primary neoplasia of the vocal cords, but confirmed paresis of the left vocal cord. Ultrasound displayed a thyroid gland with a total volume of 60 ml (left lobe: 48 ml; right lobe: 12 ml) as
| Author          | Patient     | Symptoms                                      | Radiological findings                                                                 | FNAC                                    | Therapy                                                                                       | Resection margins | Follow up                          |
|-----------------|-------------|-----------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------|-------------------|------------------------------------|
| Darouassi et al. [6] | 74-year-old female | Left lateral cervical swelling of 2 months evolution | Ultrasound and CT scan: Tumor process in the left thyroid lobe, ipsilateral submandibular lymphadenopathy | Not mentioned | Surgery: total thyroidectomy with tumor resection and ipsilateral functional lymph node dissection; Chemotherapy: doxorubicin and ifosfamide for recurrence (6 cycles) | Negative          | Local recurrence after 1 month      |
| Salama et al. [7]   | 76-year-old female | Rapidly enlarging left lower neck mass, dyspnea | Ultrasound: Bilateral heterogeneous thyroid nodules, left lobe 7.1 × 4.5 cm, right lobe 1.4 × 1.6 cm; CT-scan: left lobe large solid mass, 7 × 6 × 5 cm with heterogeneous enhancement and cystic degeneration, no calcification | Spindle cell proliferation of moderate cellularity, occasional blood vessel fragments embedded in myxoid background. Moderately atypical spindle-shaped nuclei with moderate amount of ill-defined cytoplasm. Few scattered large bizarre cells with eccentric hyperchromatic nuclei and abundant cytoplasm. Cytological diagnosis: anaplastic thyroid carcinoma | Surgery: total thyroidectomy; Radiotherapy (postoperative) | Close to the circumferential margins | Not mentioned                      |
| Kouassi et al. [8]  | 45-year-old female | Pre-existing goiter with increasing swelling, dysphonia, hoarseness | Ultrasound: confirmation of the tumor, no lymphadenopathy | Not mentioned                              | Surgery: total thyroidectomy, right sternocleidomastoid muscle and laryngeal nerve resection | Not mentioned                     | Not mentioned                      |
| Zhang et al. [9]    | 65-year-old male | Not mentioned                                  | Not mentioned                                                                          | Not mentioned                            | Surgery: total thyroidectomy, right sternocleidomastoid muscle and laryngeal nerve resection | Not mentioned                     | Dead of disease                    |

FNAC fine-needle aspiration cytology
well as a large hypoechoic nodule with microcalcification and irregular margins in the left lobe measuring $40 \times 39 \times 52$ mm, which was highly suspicious for a malignant thyroid tumor (Fig. 1). Laboratory findings were as follows: TSH 1.50 µIU/ml (reference: 0.27–4.20 µIU/ml), free T4 11.9 pg/ml (reference: 9.1–0.19.1 pg/ml), free T3 3.5 ng/l (reference: 2.6–5.1 ng/l), thyroglobulin-antibody (Anti-Tg)< 20 IU/ml (reference: < 40 IU/ml), thyroid-peroxidase-antibody (Anti-TPO) 16.2 IU/ml (reference: < 35 IU/ml), TSH receptor antibody < 0.3 IU/l (reference: < 1.7 IU/l), calcitonin < 2 pg/ml (reference: < 8 pg/ml).

Although fine-needle aspiration with cytology is the gold standard in the evaluation of suspicious thyroid nodules, we decided against it because of the new onset hoarseness suggestive of a locally invasive process and ultrasound findings indicative of a rapidly growing thyroid carcinoma, and performed a left hemithyroidectomy with central lymphadenectomy under curative intend. Intraoperative invasion of the esophageal muscle was noted, requiring tangential resection of the muscle. Importantly, all resection margins were free of tumor on intraoperative frozen section examination. Histopathological examination revealed a partial necrotic mesenchymal tumor with capsular invasion and blood vessel infiltration that spread into the perithyroidal soft tissue. Immunohistochemical staining was positive for vimentin, SMA and CD10, and partially positive for CD68/KP1, but negative for Cdk4, MDM2, Bc12, Muc-4, S100, desmin, CD34, EMA, CK AE1/3, TTF1 and TLE-1. In addition, Ki67 labeling index was up to 80% in tumor hotspot areas and immunohistochemistry showed a strong expression of CD99 in myxoid and more densely packed tumor areas, whereas staining of the remaining thyroid follicles was negative. Thus, the combination of morphological and immunohistochemical aspects indicated a high-grade MFS (Fig. 2). Moreover, a total of 8 lymph nodes were resected, and a 0.1-cm lymph node metastasis of the tumor was detected in one lymph node. Importantly, final histopathology confirmed the complete resection of the tumor with negative resection margins.

Given the diagnosis of highly aggressive MFS and due to its untypical localization, F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scan was performed 2 weeks after the operation to find a primary localized elsewhere and to complete tumor staging. Unfortunately, PET/CT-scan excluded a primary somewhere else in the body but demonstrated local recurrence with a $9.6 \times 7.1 \times 9$ cm left cervical tumor mass expanding from the esophagus to the carotid sheath that infiltrated the trachea, the front-edge of the lower cervical vertebrae and the higher thoracic vertebrae (Fig. 3). In addition, a 3-mm measuring nodule in the medial right lung lobe and locoregional lymph node metastases were detected.

After discussing the case in our multidisciplinary tumor board, an urgent radiotherapy followed by chemotherapy with doxorubicin and ifosfamide was recommended. The patient was admitted to our department of radiation oncology to receive 70 Gy.
of radiation in fractions of 2 Gy five times a week in a time frame of 7 weeks. Between the radiation sessions, he twice developed dyspnea, supraglottic edema and inspiratory stridor and had to be admitted to the intensive care unit. Both times the symptoms were alleviated with corticosteroid therapy, tracheotomy was avoided, and the patient was able to continue its radiation treatment. Two months after surgery and after the first 30 Gy of radiation, a CT scan of the thorax demonstrated a tumor mass in the ventral upper thorax infiltrating the larynx, esophagus and left common carotid artery (Fig. 4). Unfortunately, due to the tumor’s progression, its non-resectability and significantly reduced general condition of the patient, palliative care was initiated.

**Discussion**

In this report, we present a rare case of MFS of the thyroid gland. To our knowledge, only 4 cases of primary thyroid MFS have been reported in the literature so far [6–9]. Only one case report described the preoperative use of fine-needle aspiration cytology (FNAC), in which cytology revealed no evidence of MFS but anaplastic thyroid carcinoma [7]. However, considering the rapidly growing tumor with a new onset of hoarseness, we would have chosen our therapeutic strategy even without FNAC, except that we would have performed preoperative imaging to rule out distant metastasis or a primary tumor elsewhere.

MFS represents approximately 5% of all soft tissue sarcomas [3]. The term MFS was first introduced by

---

**Fig. 2** Histomorphology and immunohistochemistry of high-grade MFS of the thyroid gland. a MFS of the thyroid gland presenting as multi-nodular tumor composed of pleomorphic spindle-shaped cells infiltrating the normal thyroid parenchyma with vascular invasion (hematoxylin–eosin staining (HE), ×25). b Higher magnification demonstrates a myxoid stroma arranged along curvilinear blood vessels (HE, ×50). c Immunohistochemical staining showing strong expression of CD99 in myxoid (left) and more densely packed (right) tumor areas, while remnant thyroid follicles (arrows) stain negative for CD99 (×50). d Remnant thyroid follicles (upper right) exhibit a strong nuclear expression of TTF-1, while surrounding tumor cells remain negative (50x)
Angervall et al. in 1977 who described a group of tumors with histiocyte- and/or fibroblast-like cells, nodular and myxoid appearance, plexiform pattern of capillary-like vessels, pleomorphism of the nucleus and a large variation in cellularity, polymorphism and mitotic activity [2]. Until the working group of the WHO’s Classification of Tumors of Soft Tissue and Bones found a consensus in 2002, MFS were considered as a part of the group of malignant fibrous histiocytoma (MFH). However, with the introduction of new molecular studies and the progress of immunohistochemistry they became a distinct pathological entity [3]. Based on the degree of cellularity, pleomorphism of the nucleus and mitotic activity, MFS are classified from low- to high-grade differentiated tumors [2]. Several grading systems have been proposed, such as the Brodie and FNCLCC systems, which use four and three grades, respectively, but until today there is no uniformly accepted standard grading system that explicitly applies to MFS [1, 3].

Diagnosis of MFS is based on microscopic characteristics, such as the presence of alternating hypocellular myxoid areas and hypercellular fibrous areas with curvilinear vessels [2, 3]. Although there are no specific immunohistochemical markers for MFS, they may stain...
positively for vimentin, acid mucins and sometimes SMA or CD34 and are negative for S-100 [2, 10].

Importantly, radiological findings by imaging techniques such as CT scan and magnetic resonance imaging (MRI) may misdiagnose MFS. For example, in CT-scan low-grade MFS may be misinterpreted as a benign tumor and in MRI T2-weight signal MFS may appear as a cystic formation [10]. Moreover, the tail sign, often used for the diagnosis of MFS in MRI, seems to have neither high sensitivity nor high specificity for the differential diagnosis of MFS from other myxoid tumors [11]. Nevertheless, MRI remains currently the imaging method of choice for patients with MFS. Of note, the use of FDG-PET/CT in the diagnosis of MFS is still under debate. Whereas a number of studies demonstrated comparable results between MRI and PET/CT in the identification of locoregional recurrences, its use in the initial diagnosis of a MFS has yet to be determined [12–14].

Irrespective of the grade, MFS shows with up to 61% a high tendency towards locoregional recurrences. Therefore, surgical resection with tumor-free margins, is the standard of care and remains the only chance for cure [15]. Although lymph node metastases are rarely seen at the initial presentation of patients with MFS [16], recent studies demonstrated a frequency up to 31% for lymph node metastases among patients with recurrent distant metastasis [17]. Of note, the study by Sanfilippo et al. [18] reported that 20% of patients who progressed to metastatic disease had previously positive regional lymph nodes. In this respect, the oncologic approach should include prophylactic dissection of the locoregional lymph nodes in addition to resection of the affected thyroid lobe. In our opinion, a total thyroidectomy is not necessary because, in contrast to differentiated thyroid carcinoma, postoperative radioiodine therapy is not indicated.

However, the use of radiotherapy in MFS is still controversial. The existing case series, retrospective studies, and case reports regarding the use of radiotherapy in the treatment of MFS, mostly in an adjuvant setting, show conflicting results [1, 3, 15, 18, 19].

The role of chemotherapy in the treatment of MFS remains unclear [3]. Until today, a randomized clinical trial evaluating the use of chemotherapy specifically in MFS is missing [3]. However, there are a few case series in which chemotherapy is used for the treatment of MFS [5, 18–21].
Conclusion
The thyroid gland is a very uncommon localization for MFS and only a few cases have been reported in the literature during the past decades. Whereas imaging techniques may be helpful, the gold standard for diagnosis remains histopathology. Radical and wide surgical resection is still the cornerstone in the treatment of MFS and a close clinical follow-up combined with a CT-scan or MRI is mandatory. In addition, adjuvant radiotherapy may play a role in preventing locoregional recurrence. However, the existing data regarding radio- and chemotherapy are from retrospective studies and case series of low evidence. Accordingly, this elucidates the urgent need of multicentric and randomized controlled clinical trials that specifically focus on this aggressive tumor entity.

Abbreviations
Anti-Tg: Thyroglobulin-antibody; Anti-TPO: Thyroid-peroxidase-antibody; CT: Computed tomography; FDG: Fluorodeoxyglucose; FNAC: Fine-needle aspiration cytology; FNCLCC: Fédération Nationale des Centres de Lutte Contre Le Cancer; MFH: Malignant fibrous histiocytoma; MFS: Myxofibrosarcoma; MRI: Magnetic resonance imaging; PET/CT: Positron emission tomography/computed tomography; STS: Soft tissue sarcoma; TSH: Thyroid-stimulating hormone; WHO: World Health Organization.

Acknowledgements
Not applicable.

Author contributions
MCS wrote the first draft of the manuscript. AK and WTK performed surgery. LH and IE performed the pathological examination. MS, YM, CA, and GA contributed to the pre- and postoperative diagnostic. LFG and GA contributed to the drafting of the diagnostic findings. AK and WTK wrote the final version of the manuscript. All authors reviewed and approved the final version of the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
All data generated during this case report are included in this article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Competing interests
The authors have no competing interest.

Author details
1 Department of Surgery (A), Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 2 Institute of Pathology, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 3 Division for Specific Endocrinology, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 4 Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 5 Department of Specific Endocrinology, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 6 Department of Surgery (A), Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany. 7 Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Duesseldorf, Germany.

Received: 4 May 2022 Accepted: 12 July 2022
Published online: 25 July 2022

References
1. Teurneau H, Engellau J, Ghanem I, Vult Steyern F, Styring E. High recurrence rate of myxofibrosarcoma: the effect of radiotherapy is not clear. Sarcoma. 2019;2019:8517371.
2. Angervall L, Kindblom LG, Merck C. Myxofibrosarcoma A study of 30 cases. Acta Pathol Microbiol Scand Sect Pathol. 1977;85(2):127–40.
3. Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016;25(4):775–88.
4. Nishimura G, Sano D, Hanashi M, Yamanaka S, Tanigaki Y, Taguchi T, et al. Myxofibrosarcoma of the hypopharynx. Auris Nasus Larynx. 2006;33(1):93–6.
5. Mutter RW, Singer S, Zhang Z, Brennan MF, Aleti KR. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118(2):518–27.
6. Darouassi Y, Attifi H, Zalagh M, Harrah I, Benaria F. Myxofibrosarcoma of the thyroid gland. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):385–7.
7. Salama A, Hafez N, Abu-Sinna E, Hassouna A, Amin AA. Myxofibrosarcoma of the thyroid gland. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):385–7.
8. Kouassi YM, Tanon-Anoh MJ, Doukoure B, Assouan C, Buriama F, NyGarrta KV, et al. Thyroid localization of myxofibrosarcoma: first case in Africa. Med Tropic. 2010;70(1):70–2.
9. Zhang L, Lubin D, Sinard JH, Dickson JC, Antonescu CR, Wu H, et al. Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). Head Neck Pathol. 2022. https://doi.org/10.1007/s12105-022-01428-7.
10. Wong A, Chan W, Park R, Mirani NM, Eloy JA. Myxofibrosarcoma of the maxillary sinus. Allergy Rhinol. 2017;8(2):95–9.
11. Lefkowitz RA, Landa J, Hwang S, Zabor EC, Moskowitz CS, Agaram NP, et al. Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging. Skeletal Radiol. 2013;42(6):809–18.
12. Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma. Sarcoma. 2012;2012:960194.
13. Lim HJ, Johnny Ong CA, Tan JW, Ching Teo MC. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Crit Rev Oncol Hematol. 2019;143:1–13.
14. Park SY, Chung HW, Chae SY, Lee JS. Comparison of MRI and PET-CT in detecting the loco-regional recurrence of soft tissue sarcomas during surveillance. Skeletal Radiol. 2016;45(10):1375–84.
15. Boughzala-Bennadji R, Stoelcke E, Le Péchoux C, Méeus P, Honoré C, Attal J, et al. Localized myxofibrosarcomas: roles of surgical margins and adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(2):399–406.
16. Håglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82(1):361–7.
17. Tsuchie H, Kaya M, Nagasawa H, Emori M, Murahashi Y, Mizushima E, et al. Distant metastasis in patients with myxofibrosarcoma. Upsala J Med Sci. 2017;122(3):190–3.
18. Sandilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18(3):720–5.
19. Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20(1):80–6.
20. Elkrief A, Kazandjian S, Alcindor T. Gemcitabine-containing chemotherapy for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin: a case series. Curr Oncol. 2021;28(1):813–7.

21. Colia V, Fione M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, et al. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. Clin Sarcoma Res. 2017;7:16.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.